Resultados da busca - Francesco Schettini

Refinar Resultados
  1. 1
    Dissecting the biological heterogeneity of HER2-positive breast cancer

    Dissecting the biological heterogeneity of HER2-positive breast cancer por Francesco Schettini, Aleix Prat

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes

    A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes por Francesco Schettini, Fara Brasó‐Maristany, Nicole M. Kuderer, Aleix Prat

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer

    Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer por Claudette Falato, Francesco Schettini, Tomás Pascual, Fara Brasó‐Maristany, Aleix Prat

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  4. 4
    Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going

    Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going por Francesco Schettini, Giuseppe Buono, Cinzia Cardalesi, Isacco Desideri, Sabino De Placido, Lucia Del Mastro

    Publicado em 2016
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  5. 5
    Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

    Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment por Caterina Gianni, Michela Palleschi, Giuseppe Schepisi, Chiara Casadei, Sara Bleve, Filippo Merloni, Marianna Sirico, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Francesco Schettini, Ugo De Giorgi

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  6. 6
    The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients

    The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients por Adriana Ceci, Paola Baiardi, Mariagrazia Felisi, Maria Domenica Cappellini, V. Carnelli, Vincenzo De Sanctis, Renzo Galanello, Aurelio Maggio, Giuseppe Masera, Antonio Piga, Francesco Schettini, Ippazio Stefàno, Fernando Tricta

    Publicado em 2002
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

    CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors por Francesco Schettini, Irene De Santo, Carmen G. Rea, Pietro De Placido, Luigi Formisano, Mario Giuliano, Grazia Arpino, Michelino De Laurentiis, Fabio Puglisi, Sabino De Placido, Lucia Del Mastro

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  8. 8
    Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis

    Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis por Chiara Molinelli, Flavia Jacobs, Elisa Agostinetto, Guilherme Nader Marta, Marcello Ceppi, Marco Bruzzone, Eva Blondeaux, Francesco Schettini, Aleix Prat, Giuseppe Viale, Lucia Del Mastro, Matteo Lambertini, Evandro de Azambuja

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  9. 9
    CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

    CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial por Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó‐Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review

    Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case re... por Javier Muñoz, Sabrina Nucera, Natalia García, Isaac Cebrecos, G. Osés, Sergi Ganau, Esther Sanfeliu, Pedro Jares, Mercedes Marín‐Aguilera, Patricia Galván, Fara Brasó‐Maristany, Olga Martínez‐Sáez, Enric Cascos, Carme Font, Francesco Schettini

    Publicado em 2025
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  11. 11
    Frequency and spectrum of PIK3CA somatic mutations in breast cancer

    Frequency and spectrum of PIK3CA somatic mutations in breast cancer por Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Bárbara Adamo, María Vidal, Blanca González‐Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó‐Maristany, A. Rodríguez, Eduardo Martínez de Dueñas, Patricia Galván, Ana Belén Rodríguez, Antonio Martı́nez, Montserrat Muñoz, Aleix Prat

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis

    Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis por Francesco Schettini, Fabiola Giudici, Mario Giuliano, Massimo Cristofanilli, Grazia Arpino, Lucia Del Mastro, Fabio Puglisi, Sabino De Placido, Ida Paris, Pietro De Placido, Sergio Venturini, M. De Laurentis, Pierfranco Conté, Dejan Juric, Antonio Llombart‐Cussac, Lajos Pusztai, Aleix Prat, Guy Jérusalem, Angelo Di Leo, Daniele Generali

    Publicado em 2020
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  13. 13
    Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis

    Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis por Francesco Schettini, Sabrina Nucera, Tomás Pascual, Olga Martínez‐Sáez, Rodrigo Sánchez-Bayona, Benedetta Conte, Giuseppe Buono, Matteo Lambertini, Kevin Punie, Juan Miguel Cejalvo, Grazia Arpino, Paolo Vigneri, Daniele Generali, Eva Ciruelos, Javier Cortés, Alessandra Gennari, Montserrat Muñoz, María Vidal, Sara M. Tolaney, Aleix Prat, Guillermo Villacampa

    Publicado em 2024
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  14. 14
    23P Clinical, pathological and gene expression features of HER2-low breast cancer

    23P Clinical, pathological and gene expression features of HER2-low breast cancer por Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Giuseppe Perrone, Patricia Villagrasa, Joaquín Gavilá Gregori, Carlos H. Barrios, Aña Lluch, M. Martín Jiménez, Sabino De Placido, Aleix Prat

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

    Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study por Giuseppe Buono, Anna Crispo, Mario Giuliano, Carmine De Angelis, Francesco Schettini, Valeria Forestieri, Rossella Lauria, Michelino De Laurentiis, Pietro De Placido, Carmen G. Rea, Carmen Pacilio, Emanuela Esposito, Maria Grimaldi, Flavia Nocerino, Giuseppe Porciello, Aldo Giudice, Alfonso Amore, Anita Minopoli, Gerardo Botti, Sabino De Placido, Meghana V. Trivedi, Grazia Arpino

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Gene expression profiles of breast cancer metastasis according to organ site

    Gene expression profiles of breast cancer metastasis according to organ site por Fara Brasó‐Maristany, Laia Paré, Núria Chic, Olga Martínez‐Sáez, Tomás Pascual, Meritxell Mallafré‐Larrosa, Francesco Schettini, Blanca González‐Farré, Esther Sanfeliu, Eduardo Martínez de Dueñas, Patricia Galván, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillén, Bárbara Adamo, Reinaldo Moreno, María Vidal, Montserrat Muñoz, Aleix Prat

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

    A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies por Benedetta Conte, Fara Brasó‐Maristany, A. Rodríguez, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, María Vidal, Elia Seguí, Laura Angelats, Isabel García-Fructuoso, Raquel Gómez Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín‐Aguilera, Olga Martínez‐Sáez, Bárbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

    Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer por Francesco Schettini, S. Nucera, F Brasó-Maristany, Irene De Santo, T. Pascual, M. Bergamino, P. Galván, B. Conte, E. Seguí, I. García Fructuoso, R. Gómez Bravo, P. Rivera, A.B. Rodríguez, O. Martínez-Sáez, S. Ganau, E. Sanfeliu, B. González-Farre, María Vidal, B. Adamo, I. Cebrecos, E. Mension, G. Oses, P. Jares, S. Vidal-Sicart, M. Mollà, Montserrat Muñoz, A. Prat

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer por Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Esther Barnadas, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Aña Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer por Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Esther Barnadas, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Aña Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Errata/Corrigenda
    Salvar na lista
    Na minha lista:

Ferramentas de busca: